Search Results

You are looking at 1 - 10 of 122 items for :

  • "adrenal tumors" x
  • All content x
Clear All
Open access

J Crona, F Beuschlein, K Pacak, and B Skogseid

Introduction Clinically unapparent adrenal tumors are found in 2–10% of the population worldwide. Cases that do require treatment are enriched in risk populations particularly those with hypertension or genetic risk factors (overview in

Free access

A Lasco, E Morini, D Maglitto, A Campennì, and S Benvenga

virilizing adrenal tumor (VAT), either tumor being very rare ( Carr 1998 ). An additional cause of virilization is iatrogenic, such as use of anabolic steroids (androgens), and postmenopausal women are sensitive to even low doses of androgens ( Speroff et al

Open access

Helene Myrtue Nielsen, Alexandre How-Kit, Carole Guerin, Frederic Castinetti, Hans Kristian Moen Vollan, Catherine De Micco, Antoine Daunay, David Taieb, Peter Van Loo, Celine Besse, Vessela N Kristensen, Lise Lotte Hansen, Anne Barlier, Frederic Sebag, and Jörg Tost

Introduction Tumors developing in the adrenal gland include a heterogeneous group of adrenocortical and adrenomedullary malignancies ( Brunt & Moley 2001 , Grumbach et al . 2003 ). Most adrenal tumors are benign and non-hormone producing. However

Open access

Tiantian Liu, Taylor C Brown, C Christofer Juhlin, Adam Andreasson, Na Wang, Martin Bäckdahl, James M Healy, Manju L Prasad, Reju Korah, Tobias Carling, Dawei Xu, and Catharina Larsson

primers. Table 1 Detection of TERT promoter mutations in adrenal tumors Tumor types and subgroups Number of mutated/analyzed cases (%) Series A ( n =147) Series B ( n =52) Series A+B ( n =199) Adrenocortical tumors 3/48 (6%) 1/33 (3

Free access

Fidéline Bonnet-Serrano and Jérôme Bertherat

of adrenal tumors. The first molecular alterations were identified by the study of rare familial tumor syndromes, including adrenocortical tumors due to an identified germline mutation or epigenetic alteration ( Libé & Bertherat 2005 ). Most of these

Free access

Sisi Liu, Emmanouil Saloustros, Annabel Berthon, Matthew F Starost, Isabelle Sahut-Barnola, Paraskevi Salpea, Eva Szarek, Fabio R Faucz, Antoine Martinez, and Constantine A Stratakis

pituitary and the adrenal cortex: a source of variation in hypothalamic–pituitary–adrenal axis function; implications for pituitary and adrenal tumors . Endocrine Practice 17 941 – 948 . ( doi:10.4158/EP11061.RA ). Carney JA Gordon H Carpenter PC

Free access

Susanna Vuorenoja, Adolfo Rivero-Müller, Adam J Ziecik, Ilpo Huhtaniemi, Jorma Toppari, and Nafis A Rahman

first and fifth decades of life and are relatively more common in women than men ( Schulick & Brennan 1999 a , b ). There are still no efficient forms of therapy for adrenal tumors. The only effective treatment at this moment is complete adrenalectomy

Free access

Susanna Vuorenoja, Bidut Prava Mohanty, Johanna Arola, Ilpo Huhtaniemi, Jorma Toppari, and Nafis A Rahman

sexes expressing the inhibin-α promoter/Simian Virus (SV40) T-antigen (inhα/Tag) were originally found to produce gonadal tumors with 100% penetrance by the age of 6 months, but when gonadectomized prepubertally they produced adrenal tumors by the same

Free access

Patricia de Cremoux, Dan Rosenberg, Jacques Goussard, Catherine Brémont-Weil, Frédérique Tissier, Carine Tran-Perennou, Lionnel Groussin, Xavier Bertagna, Jérôme Bertherat, and Marie-Laure Raffin-Sanson

clinical evidence to suggest that adrenocortical tumors are more prevalent in women than in men. For example, a sex ratio of 4.2 was reported for a series of 199 adrenal tumors ( Luton et al . 1990 ). Moreover, ACC generally affects women at a younger age

Free access

R Nawar and D Aron

, Cushing’s syndrome and virilization) are more likely to have adrenal tumors. Although in many cases these features are subtle and do not prompt early diagnosis, whether one should consider these lesions to be truly ‘incidental’ is a matter of opinion